Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Theriva stock is trading higher after the company announced it was selected as a finalist for Merck's KGaA's EMEA Advance ...

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck’s ...

Theriva Biologics, a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced selection as one of five finalists ...

Founded on the principles of innovation and patient need, Theriva™ Biologics is a diversified clinical-stage company focused on developing groundbreaking therapeutics to combat cancer and related ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market Merck experts to provide ...

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the ...

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced ...

will pitch their breakthroughs to Merck KGaA representatives and the overall BIO-Europe audience. The winner will be announced following the five presentations. About Theriva™ Biologics ...

Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing ...